LDK-378 dihydrochloride(Ceritinib dihydrochloride)

Biorbyt

LDK-378 dihydrochloride(Ceritinib dihydrochloride) [1380575-43-8]

10

1380575-43-8

Research Use Only

C28H38CL3N5O3S

631.0570226

Ceritinib, also known as LDK-378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). In Phase I trials, LDK378 showed a marked clinical response in 78 patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who had progressed during or after crizotinib therapy or had not been previously treated with crizotinib. LDK378 blocks the ALK protein and stops it sending growth signals to cancer cells, which may stop them growing. Ceritinib was approved in April 2014.

Cl.Cl.CC1=C(C2CCNCC2)C=C(OC(C)C)C(NC2=NC=C(Cl)C(NC3=C(S(C(C)C)(=O)=O)C=CC=C3)=N2)=C1

12352200